Sulphonamides are a class of antimicrobial agents that were the first to demonstrate effectiveness against pyogenic bacterial infections. These compounds are derivatives of sulphanilamide, characterized by their ability to inhibit bacterial growth by interfering with bacterial synthesis pathways. Sulphonamido-chrysoidine (Prontosil red) is a specific dye included by Domagk in early research; it was found to be highly effective in treating experimental streptococcal infections in mice. When administered, Prontosil red breaks down into sulphonilamide, which is the active component responsible for its antimicrobial activity. Pyogenic bacterial infections refer to infections caused by bacteria that produce pus, such as streptococci and staphylococci, which were among the first bacterial infections effectively targeted by sulphonamides.
Sulphonamides hold a significant place in medical history as the first antimicrobial agents capable of combating pyogenic bacterial infections effectively. Their discovery marked a breakthrough in infectious disease treatment, providing a new approach to bacterial control. The dye Prontosil red was a notable example of sulphonamides used in experimental settings; it was initially tested by Domagk, who observed its high efficacy against streptococcal infections in mice. Importantly, Prontosil red does not act directly but breaks down into sulphonilamide, which exerts the antimicrobial effect. Over subsequent years, a large number of sulphonamides were produced and used extensively, reflecting their initial success. However, the widespread use of sulphonamides eventually faced challenges due to the emergence of bacterial resistance and the development of safer, more effective antibiotics. Today, their utility is limited mainly to specific cases such as malaria, where they still hold some relevance.
Sulphonamides are historically significant as pioneering antimicrobial agents that initially revolutionized the treatment of bacterial infections, though their current use is limited due to resistance and the availability of newer antibiotics.
Sulphanilamide: Sulphanilamide is the fundamental chemical compound from which all sulphonamides are derived. It serves as the core structure in the class of compounds known as sulphonamides, providing the basic framework upon which various substitutions are made to modify their properties.
N¹ substitution: This refers to the specific chemical modification made at the nitrogen atom in the N¹ position of the sulphanilamide molecule. The nature of the N¹ substitution is crucial because it influences the solubility of the compound, its potency, and its pharmacokinetic behavior, including absorption, distribution, metabolism, and excretion.
N⁴ substitution: This denotes the substitution at the nitrogen atom in the N⁴ position of the sulphanilamide molecule. The N⁴ substitution primarily governs the antibacterial activity of the sulphonamide compound, affecting its ability to inhibit bacterial growth effectively.
All sulphonamides are derivatives of sulphanilamide, meaning that they share a common core structure but differ based on the specific substitutions made at the N¹ and N⁴ positions. These structural variations are critical because they determine the pharmacological and antibacterial properties of each compound.
The N¹ substitution plays a key role in defining the solubility, potency, and pharmacokinetic characteristics of sulphonamides. Variations at this position can enhance or diminish the compound's ability to be absorbed and distributed within the body, as well as influence its overall effectiveness.
Conversely, the N⁴ substitution is primarily responsible for the antibacterial activity of the sulphonamide. Changes at this site can alter the compound's ability to inhibit bacterial growth, making it more or less effective against specific bacteria.
The chemical structure variations, specifically the substitutions at N¹ and N⁴, are fundamental in determining the properties and antibacterial activity of sulphonamides. These structural modifications allow for the tailoring of sulphonamide compounds to optimize their therapeutic efficacy and pharmacokinetic profiles.
Classification of sulphonamides (general)
Sulphonamides are classified based on their chemical structure and pharmacokinetic properties. This classification considers how the chemical makeup influences their absorption, distribution, metabolism, and excretion, as well as their spectrum of activity and duration of action. These structural and pharmacokinetic distinctions help determine their appropriate clinical use.
Types based on duration and use (implied)
While not explicitly detailed in the source, sulphonamides can be categorized according to their duration of action—short, intermediate, or long—and their specific clinical applications. These classifications influence their selection for different infections and treatment durations, ensuring optimal therapeutic outcomes.
Prototype sulphonamides
Sulfadiazine is recognized as the prototype general-purpose sulphonamide. It exemplifies the typical characteristics of sulphonamides used broadly in clinical practice, serving as a reference point for comparing other agents within this class.
Sulphonamides are classified primarily based on their chemical structure and pharmacokinetic properties. This classification aids healthcare professionals in understanding their behavior in the body and their spectrum of antibacterial activity. Different sulphonamides exhibit varying durations of action, which influences their clinical application; some are suitable for short-term use, while others are designed for longer-lasting effects. The choice of sulphonamide depends on factors such as the site of infection, severity, and required duration of therapy. Sulfadiazine stands out as the prototype sulphonamide, representing the general-purpose agent within this class. Recognizing these classifications helps in selecting the most appropriate sulphonamide agent for specific clinical scenarios, optimizing efficacy and minimizing resistance.
Understanding the classification of sulphonamides based on chemical structure and pharmacokinetics is essential for selecting the appropriate agent, ensuring effective treatment tailored to the infection type and duration needed.
Bacteriostatic activity:
Sulphonamides exhibit bacteriostatic activity, meaning they inhibit the growth and reproduction of bacteria rather than killing them outright. This activity is effective against various gram-positive and gram-negative bacteria, preventing bacterial proliferation and allowing the immune system to eliminate the pathogens.
Bactericidal concentration in urine:
The bactericidal concentration refers to the level of sulphonamides in urine that is sufficient to kill bacteria. Achieving this concentration in urine is particularly useful for treating urinary infections, as it ensures the destruction of pathogenic bacteria within the urinary tract.
Anaerobic bacteria resistance:
Anaerobic bacteria are not susceptible to sulphonamides. This means that sulphonamides are ineffective against bacteria that thrive in environments lacking oxygen, limiting their spectrum of activity to aerobic bacteria.
Chlamydiae sensitivity:
Certain organisms, including Chlamydiae, are sensitive to sulphonamides. These organisms, which include species causing trachoma, lymphogranuloma venereum, and inclusion conjunctivitis, are susceptible due to their reliance on folic acid synthesis pathways that sulphonamides inhibit. Other sensitive organisms include Actinomyces, Nocardia, and Toxoplasma.
Sulphonamides are primarily bacteriostatic agents that act against a broad range of bacteria, including various gram-positive and gram-negative species. Their mechanism involves inhibiting bacterial folate synthesis by competitively blocking the enzyme dihydropteroate synthase, which is essential for the production of folic acid (FA). Since many bacteria synthesize their own folic acid from p-aminobenzoic acid (PABA), sulphonamides, being structural analogues of PABA, effectively prevent the formation of dihydrofolic acid, a precursor for DNA synthesis. This inhibition halts bacterial growth without directly killing the bacteria.
A significant clinical advantage of sulphonamides is their ability to reach bactericidal concentrations in urine, making them particularly useful for urinary tract infections. These concentrations are sufficient to kill bacteria within the urinary tract, providing effective treatment.
However, not all bacteria are susceptible to sulphonamides. Anaerobic bacteria, which thrive in oxygen-deprived environments, are resistant and do not respond to sulphonamide therapy. This limits the spectrum of activity to aerobic bacteria.
Certain organisms, notably Chlamydiae—including those responsible for trachoma, lymphogranuloma venereum, and inclusion conjunctivitis—are sensitive to sulphonamides. Additionally, organisms such as Actinomyces, Nocardia, and Toxoplasma also show sensitivity, owing to their reliance on folic acid synthesis pathways that are targeted by these drugs.
Sulphonamides demonstrate a selective spectrum of activity, being effective against specific gram-positive and gram-negative bacteria, as well as certain organisms like Chlamydiae, Actinomyces, Nocardia, and Toxoplasma, while being ineffective against anaerobic bacteria. Their ability to reach bactericidal levels in urine highlights their clinical relevance in urinary infections, emphasizing their role in targeted antimicrobial therapy.
p-aminobenzoic acid (PABA): PABA is a para-aminobenzoic acid, a chemical compound that serves as a substrate in bacterial folate synthesis. It is structurally similar to sulphonamides, which allows these drugs to mimic PABA and interfere with bacterial metabolic processes.
Folate synthase enzyme: This enzyme catalyzes the synthesis of folic acid in bacteria by facilitating the union of PABA with pteridine residues. It is essential for bacterial growth because folic acid is a precursor for nucleic acid synthesis.
Dihydropteroate synthase: An enzyme that specifically catalyzes the formation of dihydropteroic acid by combining PABA with pteridine residues. This step is critical in the bacterial pathway for producing folic acid.
Competitive inhibition: A form of enzyme inhibition where an inhibitor competes with the natural substrate for binding to the active site of an enzyme. In this context, sulphonamides compete with PABA for the active site of dihydropteroate synthase, preventing the enzyme from catalyzing its normal reaction.
Sulphonamides are structural analogues of PABA, meaning they resemble PABA in structure but are designed to interfere with its normal function. They inhibit bacterial folate synthase by competitively binding to the enzyme's active site, specifically targeting dihydropteroate synthase. This competitive inhibition prevents the union of PABA with the pteridine residue, a necessary step in the formation of dihydropteroic acid. Without dihydropteroic acid, the subsequent synthesis of dihydrofolic acid is halted, disrupting the production of folic acid in bacteria.
This inhibition of folic acid synthesis is crucial because folic acid is essential for bacterial growth and replication. By blocking this pathway, sulphonamides effectively prevent bacteria from synthesizing the folic acid they need to produce nucleic acids, thereby inhibiting bacterial proliferation.
Humans are unaffected by sulphonamides in this pathway because they do not synthesize folic acid internally. Instead, humans obtain folic acid from their diet, making the bacterial folate synthesis pathway a selective target for these drugs. This selectivity underpins the therapeutic use of sulphonamides, allowing them to inhibit bacterial growth without harming human cells.
The selective inhibition of bacterial folate synthesis by sulphonamides, through competitive binding to dihydropteroate synthase, underpins their antibacterial action while sparing human cells that rely on dietary folic acid.
Increased PABA production: This refers to the ability of bacteria to produce larger amounts of para-aminobenzoic acid (PABA), which is a substrate for folate synthesis. By synthesizing more PABA, bacteria can outcompete sulphonamides for the enzyme's active site, thereby diminishing the drug’s inhibitory effect. This adaptive response enables bacteria to sustain folate production despite the presence of sulphonamides.
Reduced enzyme affinity: This describes a situation where the folate synthase enzyme in bacteria develops a decreased affinity for sulphonamide drugs. As a result, the enzyme binds less readily to the drug, reducing the drug’s effectiveness in inhibiting folate synthesis. This decreased affinity can arise through genetic mutations or structural changes in the enzyme, making sulphonamides less capable of binding and inhibiting folate production.
Alternative folate pathways: Some bacteria can bypass the usual folate synthesis pathway altogether by adopting different metabolic routes. These alternative pathways allow bacteria to synthesize folate or its precursors through mechanisms not targeted by sulphonamides, thus rendering the drug ineffective. This metabolic flexibility is a form of resistance that undermines the drug’s mode of action.
Bacteria develop resistance to sulphonamides primarily by increasing the production of PABA. By synthesizing more PABA, bacteria effectively saturate the enzyme’s active site, reducing the inhibitory impact of sulphonamides and allowing folate synthesis to continue unimpeded. This overproduction of PABA is a key adaptive strategy that diminishes the drug’s efficacy.
Resistance also arises from a reduction in the affinity of the folate synthase enzyme for sulphonamides. When the enzyme’s binding site undergoes structural changes or mutations, its ability to bind sulphonamides decreases. Consequently, the drug cannot effectively inhibit the enzyme, allowing folate synthesis to proceed despite the presence of the drug. This mechanism directly weakens the drug’s inhibitory capacity.
In addition to these mechanisms, some bacteria can adopt alternative pathways within folate metabolism. These pathways enable bacteria to bypass the inhibited steps targeted by sulphonamides, effectively sidestepping the drug’s action. Such metabolic adaptations provide bacteria with a means to sustain folate production even when the primary pathway is blocked, further contributing to resistance.
Bacterial resistance to sulphonamides is primarily driven by adaptive strategies such as increased PABA production, reduced enzyme affinity for the drug, and the adoption of alternative folate pathways. These mechanisms collectively undermine the efficacy of sulphonamides, making bacterial infections more difficult to treat.
Absorption from GIT: Sulphonamides are rapidly and completely absorbed from the gastrointestinal tract. This means that once administered orally, they quickly enter the bloodstream, ensuring prompt therapeutic levels.
Acetylation at N⁴: In the liver, sulphonamides undergo metabolism through a process called acetylation specifically at the nitrogen atom at position 4 (N⁴). This biochemical modification results in the formation of inactive metabolites, reducing the active drug concentration in the body over time.
Crystalluria: Crystalluria refers to the presence of crystals in the urine. It can occur when acetylated metabolites of sulphonamides are less soluble in acidic urine, leading to the formation of crystals that may cause urinary tract issues.
Renal excretion: The primary route of elimination for sulphonamides is through the kidneys via renal excretion. This process mainly involves glomerular filtration, where the drug and its metabolites are filtered from the blood into the urine for elimination.
Sulphonamides are characterized by their rapid and complete absorption from the gastrointestinal tract, ensuring effective plasma concentrations soon after administration. Once absorbed, they are transported to the liver, where they undergo acetylation at the N⁴ position. This metabolic process produces inactive metabolites, which are less pharmacologically active. A significant consequence of this acetylation is that the resulting metabolites tend to be less soluble in acidic urine, raising the risk of crystalluria. Crystalluria can lead to urinary complications if crystals form and accumulate within the urinary tract. The main route of elimination for sulphonamides and their metabolites is renal excretion, predominantly through glomerular filtration. This renal clearance process is crucial for removing the drug from the body and influences dosing considerations, especially in patients with impaired kidney function.
The metabolism of sulphonamides through N⁴ acetylation and their renal excretion are key factors that influence their safety and dosing. Understanding these processes helps in managing potential side effects like crystalluria and ensures effective therapeutic use.
Sulfadiazine is a prototype sulphonamide characterized by its rapid absorption and excellent penetration into the cerebrospinal fluid (CSF). Its pharmacokinetic profile makes it particularly preferred in the treatment of meningitis, where effective CSF concentrations are crucial for combating infection.
Sulfamethoxazole is another sulphonamide with a slower absorption rate compared to sulfadiazine. It is commonly combined with trimethoprim to produce a synergistic effect, enhancing antimicrobial efficacy. This combination is widely used in various bacterial infections.
Sulfadoxine and sulfamethopyrazine are ultra-long acting sulphonamides. They are primarily employed in the treatment of malaria due to their extended duration of action. However, their use is associated with the risk of serious skin reactions, which can be severe and potentially life-threatening.
Sulfacetamide Sodium is a highly soluble sulphonamide compound that produces a neutral solution. Its high solubility and low irritation profile make it suitable for ocular applications, especially in the treatment of eye infections.
Mafenide is a non-typical sulphonamide that contains a –CH₂– group between the benzene ring and the amino group. It is used topically, particularly in burn dressings to prevent infection. Mafenide causes a burning sensation and pain upon application to raw surfaces and functions as a carbonic anhydrase inhibitor.
Silver Sulfadiazine is a topical agent effective against a broad spectrum of bacteria and fungi, including resistant strains. It works by slowly releasing silver ions, which are responsible for its antimicrobial activity. Silver sulfadiazine is considered the most effective drug for preventing infection at burn surfaces.
Sulfadiazine is recognized as the prototype sulphonamide due to its rapid absorption and excellent CSF penetration, making it the drug of choice in meningitis cases. Its pharmacokinetic profile ensures that therapeutic levels are quickly achieved in the CSF, facilitating effective treatment of central nervous system infections.
Sulfamethoxazole has a comparatively slower absorption rate, which influences its clinical use. It is frequently combined with trimethoprim, leveraging a synergistic effect that enhances antimicrobial activity against various bacterial pathogens. This combination is widely used in clinical practice for infections such as urinary tract infections.
Sulfadoxine and sulfamethopyrazine are distinguished by their ultra-long acting properties, making them suitable for malaria treatment. Despite their efficacy, their use carries the risk of serious skin reactions, which necessitates careful monitoring during therapy.
Sulfacetamide sodium is notable for its high solubility, allowing it to produce a neutral solution that minimizes irritation. Its low irritation profile and solubility make it ideal for ocular infections, where it is used topically to treat conditions such as conjunctivitis.
Mafenide is used topically in burn dressings to prevent infection, but it is not employed for treating already infected wounds. Its chemical structure includes a –CH₂– group between the benzene ring and amino group, distinguishing it from typical sulphonamides. Application of mafenide causes a burning sensation and pain, and it functions as a carbonic anhydrase inhibitor, which can influence acid-base balance.
Silver sulfadiazine is primarily used topically on burn wounds. It is effective against a variety of bacteria and fungi, including resistant strains. Its antimicrobial action is due to the slow release of silver ions, which exert a broad-spectrum antimicrobial effect. It is considered the most effective drug for preventing infection at burn surfaces.
Individual sulphonamides possess distinct pharmacological profiles and clinical applications, ranging from rapid CSF penetration for meningitis to long-acting agents for malaria, and topical agents for burn and ocular infections.
Crystalluria
Crystalluria is a common adverse effect caused by the formation of crystals in the urine, which results from insoluble metabolites of certain drugs, notably sulphonamides. These insoluble metabolites can precipitate out of solution, leading to crystal formation that may cause urinary tract irritation or obstruction if not properly managed.
Stevens-Johnson syndrome
Stevens-Johnson syndrome is a severe hypersensitivity reaction characterized by widespread skin and mucous membrane blistering, erosion, and necrosis. It has been reported in association with long-acting sulphonamides, indicating a serious adverse effect linked to specific drug formulations.
Hemolysis in G6PD deficiency
Hemolysis refers to the destruction of red blood cells, which can occur in patients with G6PD deficiency when exposed to certain drugs like sulphonamides. In these individuals, the deficiency impairs the red blood cells' ability to handle oxidative stress, leading to increased susceptibility to hemolytic episodes upon drug exposure.
Hepatitis
Hepatitis is an inflammation of the liver that can be induced by certain drugs, including sulphonamides. This adverse effect signifies liver involvement and potential impairment of hepatic function following drug administration.
Crystalluria is a frequent adverse effect associated with sulphonamides due to the formation of insoluble metabolites. These metabolites can precipitate in the urinary tract, leading to crystal formation, which may cause discomfort or urinary complications if not detected and managed.
Long-acting sulphonamides have been linked to the development of Stevens-Johnson syndrome, a serious hypersensitivity reaction. This condition involves extensive skin and mucous membrane damage and requires immediate medical attention.
Hemolysis may occur in patients with G6PD deficiency when they are treated with sulphonamides. The deficiency impairs red blood cells' ability to counteract oxidative stress, making these cells more vulnerable to destruction upon drug exposure.
Sulphonamides can induce hepatitis, an inflammatory condition of the liver, which signifies potential hepatic toxicity associated with their use.
Additionally, sulphonamides can cause kernicterus in the newborn, a form of brain damage resulting from bilirubin accumulation, and may lead to nausea and vomiting as common side effects.
In terms of drug interactions, sulphonamides inhibit the metabolism of phenytoin and warfarin. This inhibition enhances the effects of these drugs, increasing the risk of toxicity or adverse effects. Moreover, fixed dose combinations of sulphonamides with penicillin are banned in India due to concerns over drug interactions, which could complicate treatment or lead to adverse reactions.
Awareness of the adverse effects such as crystalluria, Stevens-Johnson syndrome, hemolysis in G6PD deficiency, and hepatitis, along with understanding drug interactions—particularly with phenytoin and warfarin—is essential for the safe use of sulphonamides. Proper monitoring and cautious prescribing are vital to prevent serious complications.
Combination therapy with trimethoprim: This refers to the clinical practice of using sulphonamides in conjunction with trimethoprim to treat bacterial infections. The fixed dose combination of these two agents is known as cotrimoxazole. Trimethoprim is a diaminopyrimidine that selectively inhibits bacterial dihydrofolate reductase (DHFR), an enzyme crucial for bacterial folate synthesis. It is significantly more active—over 50,000 times—against bacterial DHFR than against the mammalian enzyme, ensuring targeted antibacterial activity without substantially affecting human folate metabolism. When combined, sulphonamides and trimethoprim act synergistically to inhibit successive steps in bacterial folate synthesis, enhancing their bacteriostatic effect.
Topical use in burns: Sulphonamides are now rarely used systemically but are applied topically in burn management to prevent infection. Silver sulfadiazine and mafenide are two topical agents employed for this purpose. Silver sulfadiazine is a sulphonamide compound that, when applied to burn wounds, helps prevent bacterial colonization and subsequent infection. Mafenide, another sulphonamide derivative, is similarly used topically to inhibit bacterial growth on burn surfaces, thereby reducing the risk of burn wound sepsis.
Ocular infections: Sulfacetamide sodium is a sulphonamide derivative used specifically for ocular infections. It is formulated for topical application to treat bacterial conjunctivitis and other eye infections. Its antibacterial properties help eliminate pathogens responsible for ocular bacterial infections, providing localized treatment with minimal systemic absorption.
Sulphonamides are now rarely used alone in clinical practice. Instead, their primary current application involves combination therapy with trimethoprim, forming the fixed dose combination known as cotrimoxazole. This combination enhances antibacterial efficacy by targeting sequential steps in bacterial folate synthesis, with trimethoprim acting on dihydrofolate reductase and sulphonamides inhibiting dihydropteroate synthase. The synergistic effect results in a potent bacteriostatic action against various bacterial pathogens.
In the context of topical applications, silver sulfadiazine and mafenide are employed specifically to prevent and treat infections in burn wounds. These topical agents are applied directly to the burn surface, providing localized antimicrobial activity that helps prevent bacterial colonization and infection, which are common complications in burn management.
For ocular infections, sulfacetamide sodium is used as a topical agent. Its application in the eye helps treat bacterial conjunctivitis and other bacterial eye infections, offering targeted antimicrobial action with minimal systemic absorption.
It is important to note that sulphonamides can inhibit the metabolism of drugs such as phenytoin and warfarin, which can enhance their effects. Additionally, fixed dose combinations of sulfonamides with penicillin are banned in India, reflecting regulatory considerations in their clinical use.
Current clinical applications of sulphonamides predominantly focus on their use in combination therapy with trimethoprim and topical applications in burn and ocular infections, emphasizing their role in targeted, localized, and synergistic antibacterial treatments.
Trimethoprim is classified as a diaminopyrimidine. It functions by selectively inhibiting bacterial dihydrofolate reductase (DHFR), an enzyme crucial for bacterial folate metabolism. This selective inhibition occurs because trimethoprim is over 50,000 times more active against bacterial DHFR than against the mammalian enzyme, ensuring minimal interference with human folate pathways at antibacterial concentrations.
Fixed dose combination refers to a pharmaceutical formulation that contains a specific, predetermined dose of each component—here, trimethoprim and sulfamethoxazole—in a single dosage form. This combination is designed to optimize synergistic antibacterial effects and improve patient compliance.
Cotrimoxazole is composed of trimethoprim and sulfamethoxazole, forming a fixed dose combination that leverages their synergistic effects to inhibit bacterial folate metabolism effectively. The combination's composition is specifically designed to maximize this synergy, which results from the complementary mechanisms of the two drugs.
Trimethoprim is a diaminopyrimidine that selectively inhibits bacterial dihydrofolate reductase, an enzyme involved in folate metabolism essential for bacterial DNA synthesis and growth. Its high selectivity ensures that at antibacterial doses, human folate metabolism remains unaffected, reducing potential toxicity.
The combination exploits the fact that both drugs have similar half-lives (t½), which allows for synchronized pharmacokinetics. This similarity ensures that both drugs maintain effective concentrations simultaneously, thereby achieving optimal synergism in inhibiting bacterial folate synthesis.
While individually both sulfamethoxazole and trimethoprim are bacteriostatic—meaning they inhibit bacterial growth—their combination becomes bactericidal (cidal) against many organisms. This enhanced activity is due to their synergistic inhibition of sequential steps in bacterial folate metabolism, leading to more effective bacterial eradication.
The composition of cotrimoxazole, as a fixed dose combination of trimethoprim and sulfamethoxazole, is specifically designed for synergistic inhibition of bacterial folate metabolism, resulting in a more potent antibacterial effect than either drug alone. The similar half-lives of both drugs ensure sustained synergism, making this combination highly effective against a broad spectrum of bacteria.
Dihydrofolate reductase inhibition: This refers to the process by which certain drugs block the activity of the bacterial enzyme dihydrofolate reductase. This enzyme is crucial for the bacterial synthesis of tetrahydrofolate, a form of folate necessary for DNA replication and cell division. Inhibition of this enzyme hampers bacterial growth and proliferation.
Synergistic bactericidal effect: This describes the enhanced killing action achieved when two drugs work together, resulting in a bactericidal effect—meaning they actively kill bacteria rather than merely inhibiting their growth. The synergy occurs because each drug targets a different step in the bacterial folate synthesis pathway, amplifying the overall bactericidal activity.
Expanded antibacterial spectrum: This term indicates that the combination of drugs can act against a broader range of bacterial organisms than either drug alone. The spectrum includes additional bacteria, such as Salmonella typhi, which are not covered by sulphonamides alone, thereby increasing the clinical utility of the drug combination.
Trimethoprim selectively inhibits bacterial dihydrofolate reductase, effectively blocking a key enzyme in bacterial folate synthesis. Importantly, it spares the human enzyme due to its higher affinity for the bacterial enzyme, which reduces potential toxicity to human cells. When combined with sulfamethoxazole, which inhibits a different step in the folate synthesis pathway, the effect shifts from bacteriostatic—merely stopping bacterial growth—to bactericidal, meaning it actively kills many bacteria. This synergistic effect significantly enhances the antibacterial efficacy of the combination.
The spectrum of activity for cotrimoxazole includes bacteria that are not covered by sulphonamides alone. Notably, it can target organisms like Salmonella typhi, expanding its usefulness in treating infections such as typhoid fever. The dual targeting mechanism also contributes to a slower development of resistance, as bacteria would need to simultaneously develop resistance to both drugs, which is less likely.
The dual mechanism of inhibiting bacterial dihydrofolate reductase and the complementary action with sulphonamides not only enhances the bactericidal effect but also broadens the antibacterial spectrum, making cotrimoxazole a more effective and versatile antimicrobial agent.
(There are no explicit dates or dated events provided in the content, so this section is omitted.)
| Aspect | Details | Authors/References |
|---|---|---|
| Introduction to Sulphonamides | First antimicrobial agents effective against pyogenic bacteria; derived from sulphanilamide; Prontosil red breaks down into active sulphonilamide | Domagk (initial research) |
| Sulphonamide Chemistry | Core structure: sulphanilamide; N¹ substitution influences solubility and pharmacokinetics; N⁴ substitution affects antibacterial activity | No specific authors mentioned |
| Classification | Based on chemical structure and pharmacokinetics; prototype: sulfadiazine; categorized by duration of action | No specific authors mentioned |
| Spectrum of Activity | Bacteriostatic against gram-positive and gram-negative bacteria; bactericidal in urine for urinary infections; ineffective against anaerobic bacteria; sensitive organisms include Chlamydiae | No specific authors mentioned |
Тествайте знанията си по Sulphonamides: History, Chemistry, and Clinical Use с 12 въпроса с множество отговори с подробни корекции.
1. What is the primary role or purpose of sulphonamides in antimicrobial therapy?
2. How should knowledge of sulphonamide pharmacokinetics influence clinical practice in administering these drugs?
Запомнете ключовите концепции на Sulphonamides: History, Chemistry, and Clinical Use с 24 интерактивни флашкарти.
Introduction — significance?
First effective antimicrobials against pyogenic bacteria.
Sulphonamide core — structure?
Derived from sulphanilamide with N¹ and N⁴ substitutions.
N¹ substitution — role?
Affects solubility, pharmacokinetics.
Импортирайте курса си и AI генерира листове, тестове и флашкарти за 30 секунди.
Генератор на листове